| Trial ID: | L4171 |
| Source ID: | NCT00368134
|
| Associated Drug: |
Vildagliptin
|
| Title: |
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: Change in HbA1c after 12 weeks | Secondary: Change in FPG after 12 weeks|Change in Fasting Lipids after 12 weeks|Change in HOMA-IR after 12 weeks|Change in HOMA-B after 12 weeks|Safety Profile after 12 weeks treatment
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
370
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-08
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2007-06-28
|
| Locations: |
Novartis Pharmaceuticals, Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00368134
|
